title: Steve Reed. Interviewed by Charlotte Schubert.
abstract: Steve Reed believes the organization he has founded has the potential to radically increase the developing world's access to vaccines for neglected diseases. The efforts of the Seattle-based Infectious Disease Research Institute (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 'swine' flu pandemic. IDRI developed an adjuvant to boost the effectiveness and supplies of flu vaccines and is making the technology available to vaccine manufacturers in developing nations. Charlotte Schubert talks to Reed about how IDRI, a 90-person operation with a $19 million annual budget, could have such a big impact.
authors.affiliation: Nature Medicine, Washington, DC, USA.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Schubert
mesh_terms: D000276:Adjuvants, Immunologic / Q000191:economics* / Q000600:supply & distribution*; D001709:Biotechnology / Q000191:economics; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000191:economics / Q000276:immunology / Q000600:supply & distribution; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D035583:Rare Diseases / Q000276:immunology / Q000517:prevention & control; D014612:Vaccines / Q000191:economics* / Q000276:immunology* / Q000600:supply & distribution
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; D014612:Vaccines